IP Library Granted Patent US 9,055,889
Granted Patent B2
US 9,055,889 · App. 13/424,715 · Granted Jun 16, 2015

Method and apparatus for breath testing

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,055,889
App. No.
13/424,715
Granted
Jun 16, 2015
Kind
B2
Abstract

A breath sampling device includes a main housing having an input chamber, a first output chamber, and a second output chamber integrally formed therein where the input chamber and the first output chamber are coupled via a first port and the input chamber and the second output chamber are coupled via a second port, and a self-sealing apparatus within the second output chamber configured to seal at least an exhaust port of the second output chamber when a predetermined amount of initial waste air fills the second output chamber. The main housing can be configured to redirect a portion of air blown therethrough towards the output chamber via the first port when the self-sealing apparatus at least seals the exhaust port. Other embodiments are disclosed.

Claims (31)

1. A breath sampling device, comprising:

a main housing having a plurality of chambers;

a blow tube for insertion within an input chamber of the main housing, wherein the input chamber comprises a first port and a second port;

a first output chamber of the main housing for capturing sample air through the first port;

a second output chamber in the main housing coupled to the input chamber through the second port of the input chamber, wherein the second output chamber comprises an exhaust port;

a self-sealing apparatus comprising one of a bladder within the second output chamber configured to fill the bladder with a predetermined amount of initial waste air to expand the bladder and causing the bladder to block the exhaust port or a float element in the form of a ball or sphere within the second output chamber configured to freely move within the second output chamber and seal the exhaust port when the predetermined amount of initial waste air fills the second output chamber;

wherein the main housing is configured to redirect a portion of air blown therethrough towards the output chamber via the first port when the float element or the bladder within the second output chamber at least seals the exhaust port.

2. The breath sampling device of claim 1 further comprising an evacuated test tube containing a vacuum and having a re-sealable membrane.

3. The breath sampling device of claim 2 , wherein the evacuated test tube is placed within the first output chamber and wherein the main housing and evacuated test tube is configured to receive a portion of the air blown through the blow tube and input chamber when the re-sealable membrane is punctured by feed-through member that resides between the input chamber and the first output chamber.

4. The breath sampling device of claim 3 , wherein the feed-through member is integrally formed within the main housing.

5. The breath sampling device of claim 3 , wherein the feed-through member is a needle assembly affixed to an aperture in an internal wall of the main housing between the input chamber and the first output chamber.

6. The breath sampling device of claim 1 , wherein the second output chamber comprises a tube having opposing constricted ends, one of the constricted ends forming the exhaust port and a second of the constricted ends forming at least a portion of the second port of the input chamber.

7. The breath sampling device of claim 1 , wherein the second output chamber and the exhaust port are integrally formed from the main housing.

8. The breath sampling device of claim 1 , wherein the main housing is a unitary housing or a housing formed of two halves made of plastic.

9. The breath sampling device of claim 1 , wherein the second output chamber is formed of a clear or substantially translucent material enabling visual confirmation when the floating element blocks the exhaust port.

10. A breath sampling device, comprising:

a main housing having an input chamber, a first output chamber, and a second output chamber integrally formed therein, wherein the input chamber and the first output chamber are coupled via a first port and the input chamber and the second output chamber are coupled via a second port;

a self-sealing apparatus within the second output chamber configured to seal at least an exhaust port of the second output chamber when a predetermined amount of initial waste air fills the second output chamber; and

wherein the main housing is configured to redirect a portion of air blown therethrough towards the output chamber via the first port when the self-sealing apparatus at least seals the exhaust port;

wherein the self-sealing apparatus comprises a bladder within the second output chamber configured to fill the bladder with the predetermined amount of initial waste air to expand the bladder and causing the bladder to block the exhaust port.

11. The breath sampling apparatus of claim 10 , wherein the bladder when filled with the predetermined amount of initial waste air to expand the bladder causes the bladder to block the exhaust port and the second port.

12. The breath sampling device of claim 10 further comprising an evacuated test tube containing a vacuum and having a re-sealable membrane.

13. The breath sampling device of claim 10 , wherein the second output chamber is formed of a clear or substantially translucent material enabling visual confirmation when the self-sealing apparatus seals the exhaust port.

14. The breath sampling device of claim 13 , wherein the evacuated test tube is placed within the first output chamber and wherein the main housing and evacuated test tube is configured to receive a portion of the air blown through the input chamber when the re-sealable membrane is punctured by a feed-through member that resides between the input chamber and the first output chamber.

15. The breath sampling device of claim 14 , wherein the feed-through member is a needle assembly affixed within an aperture in an internal wall of the main housing between the input chamber and the first output chamber.

16. The breath sampling device of claim 14 wherein the feed-through member is integrally formed within the main housing.

17. A method of sampling expelled gas using a sampling device, the sampling device comprising a main housing having an input chamber, a first output chamber, and a second output chamber integrally formed therein, wherein the input chamber and the first output chamber are coupled via a first port and the input chamber and the second output chamber are coupled via a second port, a self-sealing apparatus within the second output chamber configured to seal at least an exhaust port of the second output chamber when a predetermined amount of initial air fills the second output chamber, the method comprising:

receiving a sample of air including an initial volume of air from patient through the input chamber;

sealing the exhaust port by using at least the initial volume of air to force the self-sealing apparatus to at least block the exhaust port, wherein the self-sealing apparatus comprises one of a bladder within the seond output chamber configured to fill the bladder with the predetermined amount of initial volume of air to expand the bladder and causing the bladder to block the exhaust port or float element in the form of a ball or sphere within the second output chamber configured to freely move within the second output chamber and seal the exhaust port when the predetermined amount of initial volume of air fills the second output chamber, and

after sealing the exhaust port, redirecting air through the first port toward the output chamber, wherein a predetermined volume of air is captured within a vacuum of an evacuated tube having a sealed end that is temporarily provided access to a portion of the sample of air through the first port when the sealed end is pierced causing the vacuum to be replaced with the portion of the sample air.

18. The method of claim 17 , comprising visually confirming that the exhaust port is blocked before piercing the sealed end of the evacuated tube.

Assignments (16)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 071564/0463 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 071566/0200 →
CHANGE OF NAME Recorded May 15, 2025
From: VALEANT PHARMACEUTICALS INTERNATIONAL
To: BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 071279/0791 →
MERGER Recorded May 9, 2025
From: COMMONWEALTH LABORATORIES, LLC
To: VALEANT PHARMACEUTICALS INTERNATIONAL
Reel/Frame 071073/0432 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
ENTITY CONVERSION Recorded Jul 19, 2017
From: COMMONWEALTH LABORATORIES, INC.
To: COMMONWEALTH LABORATORIES, LLC
Reel/Frame 043251/0904 →
SECURITY INTEREST Recorded Jul 19, 2017
From: COMMONWEALTH LABORATORIES, LLC
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043046/0091 →
SECURITY AGREEMENT Recorded Dec 21, 2015
From: SPROUT PHARMACEUTICALS, INC., AS GRANTOR; UNILENS VISION INC., AS GRANTOR; COMMONWEALTH LABORATORIES, LLC, AS GRANTOR; SYNERGETICS USA, INC., AS GRANTOR
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 037357/0490 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2012
From: TRAFICANTE, LOUIS J.
To: COMMONWEALTH LABORATORIES, INC.
Reel/Frame 027893/0329 →